MOBILE VIEW  | 

TULAREMIA

Classification   |    Detailed evidence-based information

Therapeutic Toxic Class

    A) Tularemia is a highly contagious, acute febrile zoonotic disease caused by Francisella tularensis. It is associated with skin, glandular, respiratory, or gastrointestinal manifestations, depending on the route of infection and virulence (type A is the more virulent form) of the infecting strain.

Specific Substances

    1) Deerfly fever
    2) Francisella tularensis
    3) F tularensis
    4) F tularensis biovar palearctica
    5) F tularensis biovar palearctica mediasiatica
    6) F tularensis biovar palearctica japonica
    7) F tularensis biovar tularensis
    8) Ohara's disease
    9) Tularemia
    10) F TULARENSIS

Available Forms Sources

    A) FORMS
    1) Small aerobic gram-negative coccobacillus; organisms occurring in North America (type A strain) usually more virulent than Asian and European varieties (type B) (Uhari et al, 1990; Penn, 1995; McChesney & Narain, 1983).
    B) SOURCES
    1) SUMMARY
    a) Francisella tularensis is a hardy bacteria in nature, persisting for weeks to months in mud, water, and decaying animal carcasses (Jacobs, 1997). Vectors include dozens of biting and blood sucking insects. The organism may be found in tick feces, but not in salivary glands.
    2) EXPOSURE, OCCUPATIONAL
    a) Rabbit hunters, butchers, cooks, processors of pelts and frozen wild rabbit meat, agricultural workers, trappers, campers, sheep herders and shearers, mink ranchers, muskrat farmers, and microbiology laboratory workers are at high risk (McChesney & Narain, 1983; Pullen & Stuart, 1945; Dienst, 1963).
    b) Pneumonic tularemia common among farmers in endemic areas; associated with farming activities such as cutting hay for silage, handling dry hay, and threshing (Syrjala, 1985).
    c) Small epidemics have been reported among tick-infected troops on military maneuvers (Penn, 1995).
    d) In the US (Colorado), tularemia has been reported following a bite from a hamster purchased from a pet store. Pet store employees/owners and pet suppliers should inform the state health department of any recurrent animal deaths or reports of ill customers or staff (Anon, 2005)
    3) BITE, CAT
    a) Tularemia can be transmitted via bites/scratches from infected domestic cats; may be more common than previously thought (Liles & Burger, 1993; Capellan & Fong, 1993; von Schroeder & McDougall, 1993) (Quenzer, 1977).
    b) Usually results in ulceroglandular tularemia (Capellan & Fong, 1993; von Schroeder & McDougall, 1993), but typhoidal tularemia has also been reported (Liles & Burger, 1993).
    c) Diagnosis should be considered in a patient exposed to house cats with outdoor access who presents with an acute febrile illness (Liles & Burger, 1993), develops pneumonia, or fails to respond to empiric therapy for a cat bite (Capellan & Fong, 1993).
    4) GRANULOMATOUS DISEASE, CHRONIC (CGD)
    a) CGD is a group of rare inherited immune disorders associated with defective NADPH oxidase and failure of phagocytes to generate microbicidal oxygen metabolites (Maranan, 1997).
    b) Patients with CGD may be at increased risk for pneumonic tularemia and subsequent severe sequelae related to F tularensis infection because of their (a) increased susceptibility to infections with catalase-positive microorganisms and (b) impaired neutrophil function (Maranan, 1997).
    c) Both tularemia and CDG are associated with pulmonary granulomas (Maranan, 1997).
    C) USES
    1) BIOLOGICAL WARFARE
    a) Tularemia could be used as airborne agent in biological warfare; potential for use against military forces in combat and as tool of terrorists against civilians. Respiratory exposure by aerosol could cause typhoidal tularemia (septicemia) or a primary pneumonia (Franz, 1997)(McGovern et al, 1999). In the United States, tularemia was weaponized for aerosol delivery in the 1950s and 1960s. Because of the rapid onset of action, nonspecific nature of complaints, and difficulty in identifying and culturing the organism, Francisella tularensis is a potential threat (McGovern et al, 1999).

Life Support

    A) This overview assumes that basic life support measures have been instituted.

Clinical Effects

    0.2.1) SUMMARY OF EXPOSURE
    A) CAUSATIVE ORGANISM: Francisella tularensis is gram-negative, nonmotile, nonsporulating coccobacillus, and is a fastidious and slow growing bacterium. It consists of 4 subspecies: tularensis (also known as Type A and the most virulent subspecies with the highest morality rate), holarctica (also known as Type B produces a milder form of illness and rarely fatal), novicida (this subspecies is most often associated with immunocompromised humans) and mediasiatica (produces a milder infection). The organism can survive for long periods in soil, plants and water leading to contamination. It can survive in acidic environments but has limited tolerance for high temperatures compared to other enteric bacterial pathogens.
    B) EPIDEMIOLOGY: Humans are highly susceptible to F tularensis infection and it can produce severe, life-threatening illness. The form of tularemia can include: pulmonary, gastrointestinal, oropharyngeal, typhoidal, oculoglandular and ulceroglandular. The type of infection that occurs is highly dependent on the strain, dose and route of inoculation. Pulmonary tularemia can result in the highest mortality, if left untreated.
    C) TARGET POPULATION: All individuals are susceptible to tularemia.
    D) MECHANISM: The organism can invade, survive, and multiply with various host cells, particularly macrophages. The bacterium can limit the macrophages's ability to digest and eliminate the bacterium which allows for the replication and progression of the infection.
    E) TIME TO ONSET: 3 to 6 days; symptoms may occur within 1 day or up to a few weeks in some cases depending on the dose, route and the virulence of the strain of F tularensis.
    F) DURATION: Varies depending on the type and virulence of a particular strain.
    G) ROUTE OF ENTRY: Oral, inhalation, insect bite, or direct contact with a contaminated object.
    H) WITH POISONING/EXPOSURE
    1) MILD TO MODERATE TOXICITY: The following events are likely to produce mild to moderate toxicity, but may lead to more severe events:
    a) OROPHARYNGEAL: Ingestion of bacteria that colonizes in the throat leading to stomatitis, pharyngitis or tonsillitis and cervical lymphadenopathy.
    b) INTESTINAL: Abdominal pain, vomiting, and diarrhea and in severe cases bowel injury.
    c) GLANDULAR: Regional lymphadenopathy with no ulcer; most commonly involves axillary nodes.
    d) ULCEROGLANDULAR (most common form; 70% to 80% of cases): Cutaneous ulcer at site of inoculation (ie tick or deer fly bite) with painful regional lymphadenopathy. Symptoms include a sudden onset of chills, fever, and headaches. The bacteria can harbor in the lymphatics or spread systemically to the CNS, liver, kidneys, lungs, and spleen.
    e) OCULOGLANDULAR: Conjunctivitis with preauricular lymphadenopathy.
    2) SEVERE TOXICITY: The following serious events can develop:
    a) PNEUMONIC: Primary pleuropulmonary disease can develop. Onset is usually abrupt and characterized by high fever with or without relative bradycardia, severe chills, dyspnea, nonproductive cough, pleuritic chest pain, and profuse sweating.
    b) MENINGEAL: Rare occurrence; appears to arise from hematogenous spread. Typically, preceded by ulceroglandular, pharyngeal, or pneumonic involvement. It can lead to permanent brain injury in some cases.
    c) TYPHOIDAL: Febrile illness without early localizing signs and symptoms (ulcerative skin lesion and lymphadenopathy absent); patients usually appear extremely toxic; complicated by pneumonia in up to 40% of cases.
    0.2.3) VITAL SIGNS
    A) Increased temperature and pulse rate are common.

Laboratory Monitoring

    A) Chest x-ray is indicated in suspected tularemia pneumonia or patients with pulmonary signs/symptoms.
    B) Serum agglutination and ELISA tests are the basis for serological diagnosis. Biosafety level 2 is recommended for clinical laboratory work with potentially infective material, and biosafety level 3 is required for culturing the organism in large quantities.
    C) Elevated creatine kinase levels (with or without rhabdomyolysis) are associated with a poor outcome.

Treatment Overview

    0.4.2) ORAL/PARENTERAL EXPOSURE
    A) SUPPORT
    1) Ingestion of improperly cooked meat (particularly game) or contaminated water may result in tularemia; organisms may remain viable in frozen meats and animal tissues for up to 3 weeks. Symptoms may include abdominal pain, vomiting, and diarrhea and in severe cases bowel injury. Treat significant fluid loss with IV fluids.
    2) Treatment should include recommendations listed in the INHALATION EXPOSURE section when appropriate.
    0.4.3) INHALATION EXPOSURE
    A) MANAGEMENT OF MILD TO MODERATE TOXICITY
    1) Illness will vary depending on the form of tularemia contracted (ie, ulceroglandular {via insect bite; most common}, pulmonary, gastrointestinal, oropharyngeal, or typhoidal) and the infecting strain and dose. Consider early use of antibiotics for known or suspected illness; do not delay for laboratory confirmation. For intestinal illness, monitor fluid status and treat with IV fluids. Treat fever and/or pain with antipyretics and/or analgesics.
    B) MANAGEMENT OF SEVERE TOXICITY
    1) Pulmonary tularemia can cause acute illness that can lead to death, if untreated. Assess respiratory function; airway support may be indicated. Do not delay antibiotic therapy for laboratory confirmation; initially treat with parenteral antibiotics followed by oral therapy. BIOLOGIC WEAPON: Potential for use as a biologic weapon using airborne tularemia; an outbreak may occur 3 to 5 days later.
    C) DECONTAMINATION
    1) DERMAL: Exposed sites should be washed immediately with soap and water. INHALATION: Wear protective masks and follow strict barrier techniques.
    D) AIRWAY MANAGEMENT
    1) In cases of airway compromise or respiratory failure secondary to pneumonic tularemia, supportive measures may include endotracheal intubation and mechanical ventilation.
    E) ANTIBIOTICS
    1) PULMONARY TULAREMIA
    a) STREPTOMYCIN: ADULT: 1 g IM twice daily for 10 days; OR 1 to 2 g/day IM in divided doses for 7 to 10 days until the patient is afebrile for 5 to 7 days; PEDIATRIC: 15 mg/kg IM twice daily for 10 days (maximum: 2 g/day).
    b) GENTAMICIN: ADULT: 5 mg/kg IV or IM once daily for 10 days; PEDIATRIC: 2.5 mg/kg IV or IM 3 times daily for 10 days.
    2) TYPHOIDAL TULAREMIA
    a) STREPTOMYCIN: ADULT: 1 g IM twice daily for 10 days; OR 1 to 2 g/day IM in divided doses for 7 to 10 days until the patient is afebrile for 5 to 7 days; PEDIATRIC: 15 mg/kg IM twice daily for 10 days (maximum 2 g/day).
    b) GENTAMICIN: ADULT: 5 mg/kg IV or IM once daily for 7 to 14 days; PEDIATRIC: 2.5 mg/kg IV or IM 3 times daily for 7 to 14 days.
    3) BIOLOGIC WEAPON THERAPY
    a) CONTAINED CASUALTY SETTING:
    1) STREPTOMYCIN: ADULT: 1 g IM twice daily for 10 days; PEDIATRIC: 15 mg/kg IM twice daily for 10 days (should not exceed 2 g/day).
    2) GENTAMICIN: ADULT: 5 mg/kg IM or IV once daily for 10 days; PEDIATRIC: 2.5 mg/kg IM or IV 3 times daily for 10 days
    3) ALTERNATIVE CHOICES: Doxycycline, chloramphenicol and ciprofloxacin.
    b) MASS CASUALTY or POSTEXPOSURE PROPHYLAXIS:
    1) DOXYCYCLINE: ADULT: 100 mg orally twice daily for 14 days; PEDIATRIC: Children less 45 kg: 2.2 mg/kg orally twice daily for 14 days OR Children greater than 45 kg: 100 mg orally twice daily for 14 days.
    2) CIPROFLOXACIN: ADULT: 500 mg orally twice daily for 14 days; PEDIATRIC: 15 mg/kg orally twice daily for 14 days (maximum:1 g/day).
    F) ANTIPYRETICS/ANALGESICS
    1) ASPIRIN (Adults only) or ACETAMINOPHEN: 650 mg (children: 15 mg/kg) orally every 4 to 6 hours or IBUPROFEN: 800 mg (children 5 to 10 mg/kg) every 8 hours.
    G) PATIENT DISPOSITION
    1) OBSERVATION CRITERIA: A patient with suspected tularemia likely needs to be admitted for antibiotic therapy.
    2) ADMISSION CRITERIA: Patients require admission for observation and administration of antibiotic therapy. Acutely ill patients in whom the diagnosis is uncertain require hospitalization for further evaluation.
    3) CONSULT CRITERIA: Infectious disease consult should be obtained for patients in whom the diagnosis is uncertain or who have persistently high fever.
    H) PITFALLS
    1) Francisella tularensis is a slow growing bacterium; treatment should be started if there is suspicion of exposure. Gastrointestinal illness may present similar to other foodborne illnesses. Obtain a complete history of possible tick or deer fly bites in patients that present 3 to 6 days or longer with a sudden onset of fever, chills and headache.
    I) TOXICOKINETICS
    1) A gram-negative, nonmotile, nonsporulating coccobacillus that can result in severe illness and possible death. The infective dose can be as few as 10 organisms via inhalation, however, larger doses (approximately 1 to 10 million) are needed to produce gastrointestinal illness. Several factors determine the degree of illness and include the infective strain (virulence), dose, and route of exposure. Gastrointestinal tularemia usually produces a milder illness, while oropharyngeal can lead to a secondary pneumonic tularemia due to the spread of infection. Typhoidal tularemia (F tularensis Type A) can have a fatality rate of 60% if left untreated, and ulceroglandular tularemia (most common type of tularemia) has a fatality rate of less than 3%.
    J) DIFFERENTIAL DIAGNOSIS
    1) Other sources of foodborne illness; pneumonia (bacterial or viral forms), viral meningitis, pharyngitis or tonsillitis (other bacterial or viral forms).
    0.4.4) EYE EXPOSURE
    A) SUPPORT
    1) Oculoglandular tularemia occurs when the portal of entry is the eye. Painful inflammation of the conjunctivae and edema of the eyelid develop. In cases of accidental eye splashes of fluids containing F tularensis, immediately flush the eyes with water.
    2) Treatment should include recommendations listed in the INHALATION EXPOSURE section when appropriate.
    0.4.5) DERMAL EXPOSURE
    A) OVERVIEW
    1) SUPPORT
    a) Tularemia may be contracted from exposure to mucous membranes, handling an infected animal, or an open wound in a laboratory setting. Exposed skin should be thoroughly washed.
    b) Treatment should include recommendations listed in the INHALATION EXPOSURE section when appropriate.
    0.4.7) BITES/STINGS
    A) SUPPORT
    1) Empiric antibiotic therapy must be instituted on clinical and historical grounds without laboratory confirmation in seriously ill patients with strong suspicion of active disease. Supportive measures include bed rest and antipyretics/analgesics.
    B) TICK REMOVAL
    1) Carefully inspect patient's skin, hair, and scalp for ticks. If present, remove with blunt, curved forceps, tweezers, or fingers protected with rubber gloves or tissue.
    2) ABSCESS DRAINAGE (Ulceroglandular): Indicated for fluctuant areas of abscess formation.
    C) ANTIBIOTICS
    1) RECOMMENDATIONS for known or suspected ULCEROGLANDULAR TULAREMIA:
    a) STREPTOMYCIN: ADULT: 30 mg/kg/day IM in 2 divided doses for 7 to 10 days (maximum 2 g/day); PEDIATRIC: 30 mg/kg/day IM in 2 divided doses for 7 to 10 days (maximum 2 g/day).
    b) GENTAMICIN: ADULT: 3 to 5 mg/kg/day IV or IM in 3 divided doses for 7 to 10 days; PEDIATRIC: 6 mg/kg/day IV or IM in 3 divided doses for 7 to 10 days.
    c) DOXYCYCLINE: Do NOT use as a first line agent: ADULT: 100 mg orally twice daily for 14 days; PEDIATRIC: Children less than 45 kg: 2.2 mg/kg orally twice daily for 14 days OR Children greater than 45 kg: 100 mg orally twice daily for 14 days.
    d) Add chloramphenicol if evidence of meningitis.
    e) CIPROFLOXACIN: ADULT: 500 mg orally twice daily for 14 days; PEDIATRIC: 15 mg/kg orally twice daily for 14 days (maximum 1 g/day)
    D) ANTIPYRETICS/ANALGESICS
    1) Indicated for control of fever, headache, and muscle pain. Onset of symptoms can be sudden.
    2) ASPIRIN (Adults only) or ACETAMINOPHEN: 650 mg (children: 15 mg/kg) orally every 4 to 6 hours or IBUPROFEN: 800 mg (children 5 to 10 mg/kg) every 8 hours.

Range Of Toxicity

    A) TOXICITY: Mortality is less than 2% if treated; can be 30% in cases of typhoidal tularemia with pneumonia. Risk of infection related to degree of exposure and virulence of the organism. INHALATION: As few as 10 organisms can result in illness. INGESTION: Larger doses of bacteria (approximately 1 to 10 million) are needed to produce gastrointestinal infection. The organism can survive long periods.

Summary Of Exposure

    A) CAUSATIVE ORGANISM: Francisella tularensis is gram-negative, nonmotile, nonsporulating coccobacillus, and is a fastidious and slow growing bacterium. It consists of 4 subspecies: tularensis (also known as Type A and the most virulent subspecies with the highest morality rate), holarctica (also known as Type B produces a milder form of illness and rarely fatal), novicida (this subspecies is most often associated with immunocompromised humans) and mediasiatica (produces a milder infection). The organism can survive for long periods in soil, plants and water leading to contamination. It can survive in acidic environments but has limited tolerance for high temperatures compared to other enteric bacterial pathogens.
    B) EPIDEMIOLOGY: Humans are highly susceptible to F tularensis infection and it can produce severe, life-threatening illness. The form of tularemia can include: pulmonary, gastrointestinal, oropharyngeal, typhoidal, oculoglandular and ulceroglandular. The type of infection that occurs is highly dependent on the strain, dose and route of inoculation. Pulmonary tularemia can result in the highest mortality, if left untreated.
    C) TARGET POPULATION: All individuals are susceptible to tularemia.
    D) MECHANISM: The organism can invade, survive, and multiply with various host cells, particularly macrophages. The bacterium can limit the macrophages's ability to digest and eliminate the bacterium which allows for the replication and progression of the infection.
    E) TIME TO ONSET: 3 to 6 days; symptoms may occur within 1 day or up to a few weeks in some cases depending on the dose, route and the virulence of the strain of F tularensis.
    F) DURATION: Varies depending on the type and virulence of a particular strain.
    G) ROUTE OF ENTRY: Oral, inhalation, insect bite, or direct contact with a contaminated object.
    H) WITH POISONING/EXPOSURE
    1) MILD TO MODERATE TOXICITY: The following events are likely to produce mild to moderate toxicity, but may lead to more severe events:
    a) OROPHARYNGEAL: Ingestion of bacteria that colonizes in the throat leading to stomatitis, pharyngitis or tonsillitis and cervical lymphadenopathy.
    b) INTESTINAL: Abdominal pain, vomiting, and diarrhea and in severe cases bowel injury.
    c) GLANDULAR: Regional lymphadenopathy with no ulcer; most commonly involves axillary nodes.
    d) ULCEROGLANDULAR (most common form; 70% to 80% of cases): Cutaneous ulcer at site of inoculation (ie tick or deer fly bite) with painful regional lymphadenopathy. Symptoms include a sudden onset of chills, fever, and headaches. The bacteria can harbor in the lymphatics or spread systemically to the CNS, liver, kidneys, lungs, and spleen.
    e) OCULOGLANDULAR: Conjunctivitis with preauricular lymphadenopathy.
    2) SEVERE TOXICITY: The following serious events can develop:
    a) PNEUMONIC: Primary pleuropulmonary disease can develop. Onset is usually abrupt and characterized by high fever with or without relative bradycardia, severe chills, dyspnea, nonproductive cough, pleuritic chest pain, and profuse sweating.
    b) MENINGEAL: Rare occurrence; appears to arise from hematogenous spread. Typically, preceded by ulceroglandular, pharyngeal, or pneumonic involvement. It can lead to permanent brain injury in some cases.
    c) TYPHOIDAL: Febrile illness without early localizing signs and symptoms (ulcerative skin lesion and lymphadenopathy absent); patients usually appear extremely toxic; complicated by pneumonia in up to 40% of cases.

Vital Signs

    3.3.1) SUMMARY
    A) Increased temperature and pulse rate are common.
    3.3.3) TEMPERATURE
    A) Tularemia presents as an acute febrile illness, regardless of specific syndrome; fever present in >85% of patients (Uhari et al, 1990; Jacobs & Narain, 1983; Evans et al, 1985).
    1) Fever begins abruptly; often associated with chills; usually continuous or mildly remittent pattern with elevations of 40 to 41.7 C reported; typically higher (greater than 40 degrees C) in typhoidal form and is poor prognostic sign (Uhari et al, 1990; Giddens et al, 1957; Dienst, 1963; Jacobs & Narain, 1983; Evans et al, 1985; Christenson, 1984).
    2) When present, a pulse-temperature dissociation (relative bradycardia) should increase clinical suspicion of typhoidal tularemia (Liles & Burger, 1993).
    3) May persist for weeks to months in untreated cases (Anon, 2005; Jacobs et al, 1985) (Francis, 1925)(Evans et al, 1985).
    3.3.5) PULSE
    A) Pulse rate increases, but not as high as expected in a febrile illness (Dienst, 1963). When present, a pulse-temperature dissociation should increase clinical suspicion of typhoidal tularemia (Liles & Burger, 1993).

Heent

    3.4.3) EYES
    A) OCULOGLANDULAR tularemia may present with any of the following clinical manifestations -
    1) PHOTOPHOBIA: Present occasionally in typhoidal tularemia; typical symptom in oculoglandular form (Hughes, 1965; Jacobs & Narain, 1983; Dienst, 1963; Billings et al, 1998; Steinemann et al, 1999).
    2) EYE PAIN: Primary symptom of oculoglandular tularemia (Halperin et al, 1985; Jacobs & Narain, 1983) (Francis, 1925) (Guerrant et al, 1976a; Hughes, 1965; Chappell et al, 1981) (Steinemann et al, 1999).
    3) LACRIMATION: Typical symptom of oculoglandular tularemia (Dienst, 1963; Billings et al, 1998; Steinemann et al, 1999).
    4) EYE DISCHARGE: Mucopurulent or watery ocular discharge may occur in oculoglandular form (Halperin et al, 1985; Hughes, 1965; Billings et al, 1998; Steinemann et al, 1999).
    5) EYE LESION: Small, multiple, yellowish nodules with shallow necrotic ulcers in palpebral conjunctivae or sclerae characteristic of oculoglandular tularemia (Jacobs & Narain, 1983; Halperin et al, 1985) (Francis, 1925)(Hughes, 1965; Chappell et al, 1981; Billings et al, 1998; Steinemann et al, 1999).
    6) CONJUNCTIVAL INJECTION: Conjunctiva typically reddened in oculoglandular form (Christenson, 1984; Guerrant et al, 1976a; Hughes, 1965; Chappell et al, 1981; Dienst, 1963; Billings et al, 1998; Steinemann et al, 1999).
    3.4.6) THROAT
    A) THROAT PAIN: Presenting symptom in 15% to 40% of patients; more common in children (Evans et al, 1985; Christenson, 1984; Jacobs et al, 1985). May be presenting symptom of oropharyngeal, typhoidal, or ulceroglandular tularemia; throat may not be clinically inflamed (Caruso et al, 1983; Evans et al, 1985; Jacobs et al, 1985; Parkhurst & San Joaquin, 1990; Everett & Templer, 1980; Luotonen et al, 1986; Dienst, 1963). Pharyngeal ulcers may accompany aerosol-induced tularemia (McGovern et al, 1999).
    1) In oropharyngeal tularemia, patients may complain of "choking" and excruciating pain on swallowing (Everett & Templer, 1980; Nordahl et al, 1993a).
    B) TONSILLAR EXUDATE: In oropharyngeal tularemia, tonsils often markedly reddened and swollen and covered by thick, gray exudate, which may extend onto lateral pharyngeal walls. The pharyngitis is unresponsive to penicillin, and routine cultures are negative (Caruso et al, 1983; Parkhurst & San Joaquin, 1990; Everett & Templer, 1980) (Markowitz, 1985) (Luotonen et al, 1986; Wills et al, 1982; Dienst, 1963; Nordahl et al, 1993a).

Cardiovascular

    3.5.2) CLINICAL EFFECTS
    A) PERICARDITIS
    1) WITH POISONING/EXPOSURE
    a) Pericarditis is uncommon; associated with pericardial friction rub and ECG abnormalities such as ST and T wave changes (Evans et al, 1985).

Respiratory

    3.6.2) CLINICAL EFFECTS
    A) PNEUMONIA
    1) WITH POISONING/EXPOSURE
    a) Inhalation of Francisella tularensis organisms may result in a septicemic typhoidal disease or a primary pneumonia, which may be rapidly fatal. In a biologic terrorist attack, pneumonic tularemia is a primary concern. Clinical manifestations include fever, cough, minimal or no sputum production, and pleuritic chest pain. Physical findings are similar to those of an atypical pneumonia and may include rales, pleural friction rubs, and signs of consolidation or effusions (McGovern et al, 1999; Gill & Cunha, 1997; Garrett, 1995; Langley & Campbell, 1995).
    1) Radiographic findings are variable and nonspecific, but may include infiltrates, cavitation, hilar adenopathy, pleural effusions, pneumothorax, and ARDS.
    2) Clinical course may be rapidly progressive and fulminant. Without antibiotic treatment, mortality rates range from 30% to 60%. With therapy, mortality drops to 1% to 2.5%.
    3) Tularemia presenting as a solitary pulmonary nodule following syngeneic peripheral blood stem cell transplantation has been reported (Naughton et al, 1999).
    b) PNEUMONIC TULAREMIA
    1) CASE SERIES: In the summer of 2000, 15 cases of confirmed tularemia were reported on Martha's Vineyard. Of those cases, 11 had primary pneumonic tularemia, 2 had ulceroglandular disease (fever with skin ulcers and lymphadenopathy) and 2 had fever and malaise, but no localizing signs. All cases were male except one with a median age of 43 years (range, 13 to 59). One death was reported in a 43-year-old man of primary pneumonic tularemia following a delay in seeking care. Francisella tularensis type A was cultured from blood and lung tissue. Risk factors associated with this outbreak were found to be lawn mowing and brush cutting (Feldman et al, 2001). The authors suggested that F. tularensis was shed in animal excreta, and persisted in the environment, and infected individuals via inhalation after mechanical aerosolization.
    B) COUGH
    1) WITH POISONING/EXPOSURE
    a) Cough is present in one third of patients overall and in two thirds of those with pneumonia; more commonly it is dry, hacking, and nonproductive of sputum (Evans et al, 1985; Dienst, 1963) (Syrjala, 1985). Dry cough and retrosternal chest pain may be only clues to respiratory involvement in typhoidal form (Penn, 1995).
    C) CHEST PAIN
    1) WITH POISONING/EXPOSURE
    a) Pleuritic chest pain or retrosternal discomfort present in 20% of patients overall and in 40% to 45% of patients with pneumonia (Evans et al, 1985) (Syrjala, 1985). Dry cough and retrosternal pain may be only clues to respiratory involvement in typhoidal form (Penn, 1995).
    D) DYSPNEA
    1) WITH POISONING/EXPOSURE
    a) Dyspnea is a complaint in 25% of patients with pneumonia (Syrjala, 1985)(Evans et al, 1985; Dienst, 1963).
    E) SPUTUM ABNORMAL - AMOUNT
    1) WITH POISONING/EXPOSURE
    a) Cough is typically nonproductive; increased sputum production occurs in about one third of cases (Evans et al, 1985).
    F) DISORDER OF RESPIRATORY SYSTEM
    1) WITH POISONING/EXPOSURE
    a) Signs of pulmonary infection may be diffuse (moist rales throughout lung; 55% to 60%) or localized (rales, dullness, bronchial breathing, increased vocal fremitus, friction rubs; 40% to 45%) (Dienst, 1963).
    G) HEMOPTYSIS
    1) WITH POISONING/EXPOSURE
    a) Hemoptysis is present in about 10% of patients with pneumonia (Evans et al, 1985).
    H) ACUTE LUNG INJURY
    1) WITH POISONING/EXPOSURE
    a) Acute respiratory distress syndrome is a rare, life-threatening complication of tularemia pneumonia; it is characterized by extensive bilateral pulmonary infiltration on chest films and severe hypoxia; it may require a high concentration of oxygen with PEEP during initial 72 hours for adequate oxygenation (Sunderrajan et al, 1985).

Neurologic

    3.7.2) CLINICAL EFFECTS
    A) INCREASED MUSCLE TONE
    1) WITH POISONING/EXPOSURE
    a) NUCHAL RIGIDITY may be present in typhoidal tularemia (Dienst, 1963; Giddens et al, 1957).
    B) HEADACHE
    1) WITH POISONING/EXPOSURE
    a) Occurs in 45% to 75% of patients; often frontal and usually severe (Evans et al, 1985; Christenson, 1984). Less common in children (5% to 10%) (Uhari et al, 1990; Giddens et al, 1957; Jacobs et al, 1985; Dienst, 1963).
    C) ALTERED MENTAL STATUS
    1) WITH POISONING/EXPOSURE
    a) Delirium, stupor, and marked restlessness are common in patients with acute toxemia even without CNS infection (Dienst, 1983) (LeDoux, 2000).
    D) ATAXIA
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: A 61-year-old man developed a 2-day history of difficulty walking and was admitted with slight delirium and mild ataxia on finger-to-nose, heel-to-shin, and rapid-alternating-movement testing. The patient also had moderate to severe gait ataxia and marked truncal ataxia in both the seated and standing position. Blood cultures were positive for Francisella tularensis and the patient was treated successfully with doxycycline, gentamicin, and ciprofloxacin with complete resolution of symptoms (LeDoux, 2000). It was suspected the infection was due to the consumption of deer meat approximately 2 weeks prior to symptoms.
    E) MENINGITIS
    1) WITH POISONING/EXPOSURE
    a) Meningeal tularemia is a rare occurrence. It appears to arise from hematogenous spread, and is typically preceded by ulceroglandular, pharyngeal, or pneumonic involvement. It may occur with no documented history of tick bite or other animal contact (Rodgers, 1998) (Tarnvik et al, 1997) (Lovell, 1986)(Hutton & Everett, 1985; Harper et al, 1986) (Hill, 1990) (Alfes & Ayers, 1990).
    b) Diagnosis is often missed or delayed, and is characterized by headache, neck stiffness, and delirium. The majority of patients have multisystem involvement at the time diagnosis of meningitis is made (Rodgers, 1998) (Tarnvik et al, 1997; Hutton & Everett, 1985; Harper et al, 1986) (Lovell, 1986) (Hill, 1990)(Alfes & Ayers, 1990).
    c) CSF findings are nonspecific and include less than 1000 WBC/mm(3), with mononuclear pleocytosis; protein level greater than 100; glucose level less than 30 mg/mL; may be bloody (Rodgers, 1998) (Hutton & Everett, 1985; Harper et al, 1986) (Lovell, 1986)(Alfes & Ayers, 1990).
    d) Meningitis may not respond to standard courses of streptomycin or gentamicin; combination therapy with doxycycline or chloramphenicol may be required (Rodgers, 1998)(Hutton & Everett, 1985; Alfes & Ayers, 1990).

Gastrointestinal

    3.8.2) CLINICAL EFFECTS
    A) VOMITING
    1) WITH POISONING/EXPOSURE
    a) GI symptoms, including vomiting, occur in 15% to 20% of patients; more common in typhoidal form (Evans et al, 1985; Christenson, 1984; Jacobs & Narain, 1983; Giddens et al, 1957).
    B) DIARRHEA
    1) WITH POISONING/EXPOSURE
    a) Presenting symptom in 10% of patients (Evans et al, 1985).
    b) Frequent symptom in typhoidal tularemia; may be presenting sign; usually loose and watery but may be bloody (Jacobs & Narain, 1983; Giddens et al, 1957; Dienst, 1963).
    c) Gastrointestinal tularemia associated with acute watery diarrhea (Harrell & Whitaker, 1985); rarely, bloody diarrhea or acute bleeding with minimal diarrhea may occur secondary to superficial colonic ulcerations (Penn, 1995).
    C) ABDOMINAL PAIN
    1) WITH POISONING/EXPOSURE
    a) Presenting symptom in 10% of cases (Evans et al, 1985; Giddens et al, 1957).
    b) Gastrointestinal tularemia associated with cramping abdominal pain (Harrell & Whitaker, 1985).
    D) DYSPHAGIA
    1) WITH POISONING/EXPOSURE
    a) Marked difficulty in swallowing typical symptom of oropharyngeal tularemia (Everett & Templer, 1980).

Hepatic

    3.9.2) CLINICAL EFFECTS
    A) LARGE LIVER
    1) WITH POISONING/EXPOSURE
    a) In one study, 2 of 73 patients had evidence of enlarged liver by percussion; extension of liver below costal margin noted in additional 18 patients (Evans et al, 1985).
    b) More common in children; palpation usually painful (Evans et al, 1985; Jacobs et al, 1985).
    B) SPLENOMEGALY
    1) WITH POISONING/EXPOSURE
    a) Present in about 15% of cases; more common in children; palpation usually painful (Evans et al, 1985; Jacobs et al, 1985).
    b) Tularemia should be considered in any patient with a febrile illness and splenomegaly (Garver et al, 1994).
    c) COMPLICATIONS
    1) Splenic abscess may be associated with disseminated infection, particularly in children. Tularemia should be considered in any patient with a febrile illness and splenomegaly, or CT or US findings suggestive of splenic abscess (Garver et al, 1994).

Genitourinary

    3.10.2) CLINICAL EFFECTS
    A) ACUTE RENAL FAILURE SYNDROME
    1) WITH POISONING/EXPOSURE
    a) Acute renal failure is rare; it may occur secondary to tubular necrosis, exudative glomerulonephritis, interstitial nephritis; frequently important contributing factor to death in fatal cases (Giddens et al, 1957; Dienst, 1963).
    b) Typhoidal tularemia with renal failure is associated with poor prognosis (Penn & Kinasewitz, 1987; Giddens et al, 1957).
    c) CASE REPORT: A 64-year-old man with a history of training dogs was found comatose in his home, and was admitted with evidence of acute renal failure. The patient was treated for acute renal failure and given intravenous ceftriaxone. However, the patient's condition deteriorated and he died 13 days after admission. Two weeks after his death, F. tularensis was isolated from blood cultures by the State laboratory (Centers for Disease Control and Prevention, 2001).

Dermatologic

    3.14.2) CLINICAL EFFECTS
    A) BITE - WOUND
    1) WITH POISONING/EXPOSURE
    a) Inoculation through tick bites often produces lesions on lower extremities, head, back, abdomen, or in concealed body areas such as axilla, groin, or intergluteal region (Lopez, 1982) (Evans et al, 1985; Pullen & Stuart, 1945; Guerrant et al, 1976a).
    b) History of tick exposure often absent in patients with pneumonic tularemia (McChesney & Narain, 1983).
    B) DERMATITIS
    1) WITH POISONING/EXPOSURE
    a) SUMMARY
    1) LOCATION: Hand and fingers following contact with infected animals. Inoculation through bites often produces lesions on lower extremities, abdomen, back, head, or in concealed body areas such as axilla, groin, or intergluteal area (Evans et al, 1985)( Lopez, 1982) (Francis, 1925)(Giddens et al, 1957).
    2) COURSE: Macular, erythematous lesion appears at site of inoculation 48 hours after entry of organism; rapidly becomes pruritic papule that enlarges and ulcerates (Francis, 1925 )(Giddens et al, 1957; Dienst, 1963).
    b) MACULOPAPULAR RASH
    1) Initial lesion macular, erythematous lesion at site of inoculation that rapidly becomes pruritic papule; papule becomes painful and swollen, causing skin to become taut, thick, shiny, and, rarely, fluctuant before ulcerating (Francis, 1925) (Giddens et al, 1957; Dienst, 1963).
    c) SKIN ULCERATION
    1) Occurs about 96 hours after inoculation; papule suppurates in center, leaving dirty, shallow ulcer 3 to 5 mm in diameter with grey necrotic base, irregular undermined firm edges, and small erythematous border; occasionally may be multiple. Eschar formation is common at the bite site (Giddens et al, 1957)(Francis, 1925)(Dienst, 1963; Evans et al, 1985; Senol et al, 1999; Kodama et al, 1994). Skin sloughing at the bite site occurred a week after a 3-year-old boy developed tularemia after he was bitten on the left ring finger by a pet hamster (Anon, 2005).
    d) CELLULITIS
    1) CASE REPORT: An 11-year-old girl developed cellulitis of the forearm which did not improve with an oral cephalosporin. The child recovered after doxycycline therapy was started for suspected tularemia; paired serum titers showed an increase in antibodies against F. tularensis. A week before becoming ill the child had been exposed to a rabbit that she had skinned and tanned herself, that had been killed by the family dog (Centers for Disease Control and Prevention, 2001).
    e) RASH
    1) Present in up to 20% of cases; located on hands, arms, legs; primarily occurs in typhoidal form; may be macular, maculopapular, pustular, or blotchy; usually bilateral and distributed symmetrically (Wills et al, 1982; Evans et al, 1985; Christenson, 1984; Jacobs & Narain, 1983; Pullen & Stuart, 1945).
    C) BUBO
    1) WITH POISONING/EXPOSURE
    a) Buboes may occur in untreated or misdiagnosed cases, particularly those infected with type A strains, lymph nodes become caseous and form suppurative buboes (Tarnvik et al, 1997; Penn, 1995).
    b) A high incidence of late suppuration (following antibiotic therapy) in children is reported. It occurred in a third of pediatric patients in one series (Jacobs et al, 1985).

Musculoskeletal

    3.15.2) CLINICAL EFFECTS
    A) MUSCLE PAIN
    1) WITH POISONING/EXPOSURE
    a) Generalized muscle aches are a presenting symptom in one third to one half of cases; more common in children (Evans et al, 1985; Jacobs & Narain, 1983; Christenson, 1984; Dienst, 1963).
    b) Muscle pain is characteristic symptom of typhoidal tularemia(Evans et al, 1985; Jacobs & Narain, 1983; Christenson, 1984; Dienst, 1963).
    B) JOINT PAIN
    1) WITH POISONING/EXPOSURE
    a) Joint pain is present in 8% to 15% of cases (Evans et al, 1985; Christenson, 1984).
    C) RHABDOMYOLYSIS
    1) WITH POISONING/EXPOSURE
    a) Rhabdomyolysis may occur in severely ill patients. Pathology of muscle injury not elucidated but may be caused by direct involvement of skeletal muscle (Kaiser, 1985) (Klotz et al, 1987).
    b) Tularemia associated with the triad of bacteremia, pneumonia, and rhabdomyolysis has been described (Klotz et al, 1987; Provenza et al, 1986).

Immunologic

    3.19.2) CLINICAL EFFECTS
    A) LYMPHADENOPATHY
    1) WITH POISONING/EXPOSURE
    a) Cutaneous multiplication of organisms can allow the organism to spread to lymph nodes, and then to the blood. Cervical lymphadenopathy is a presenting manifestation in 50% of patients; more common in children; multiple nodes are usually involved (Jacobs et al, 1985; Evans et al, 1985) (Markowitz, 1985) (McGovern et al, 1999; Fisher, 1996).
    b) Direct invasion of pharynx from ingestion of contaminated meat produces tender, enlarged cervical lymph nodes (Everett & Templer, 1980; Caruso et al, 1983; Parkhurst & San Joaquin, 1990; Luotonen et al, 1986; Wills et al, 1982).
    c) Typical presenting feature of occuloglandular tularemia; nodes may be exquisitely tender (Francis, 1925) (Halperin et al, 1985; Guerrant et al, 1976a; Hughes, 1965; Pullen & Stuart, 1945).
    d) CASE REPORT: A week after a 3-year-old boy was bitten on the left ring finger by a pet hamster, he developed fever, malaise, painful left axillary lymphadenopathy, and skin sloughing at the bite site. Serologic test was positive for Francisella tularensis at a titer of 4,096 and the isolate was identified by CDC as type B (Anon, 2005).
    e) PREAURICULAR LYMPHADENOPATHY
    1) Preauricular lymphadenopathy is a presenting sign in 8% of patients (Evans et al, 1985). It is a common finding in oculoglandular syndrome; nodes may be exquisitely tender (Halperin et al, 1985; Guerrant et al, 1976a; Pullen & Stuart, 1945; Chappell et al, 1981; Billings et al, 1998).
    f) COMPLICATIONS
    1) BUBOES: It may occur in untreated or misdiagnosed cases, particularly those infected with type A strains, lymph nodes become caseous and form suppurative buboes (Tarnvik et al, 1997; Penn, 1995).
    2) A high incidence of late suppuration (following antibiotic therapy) in children is reported. It has been noted in one third of pediatric cases in one series (Jacobs et al, 1985).
    3) Ulceroglandular infection may result in a lymphadenopathy that can persist for several months (Billings et al, 1998).

Monitoring Parameters Levels

    4.1.1) SUMMARY
    A) Chest x-ray is indicated in suspected tularemia pneumonia or patients with pulmonary signs/symptoms.
    B) Serum agglutination and ELISA tests are the basis for serological diagnosis. Biosafety level 2 is recommended for clinical laboratory work with potentially infective material, and biosafety level 3 is required for culturing the organism in large quantities.
    C) Elevated creatine kinase levels (with or without rhabdomyolysis) are associated with a poor outcome.
    4.1.2) SERUM/BLOOD
    A) HEMATOLOGIC
    1) Leukocyte count may be normal or elevated (3000 to 24,000/mm(3); mean, 11,000), regardless of clinical syndrome. Cannot be used for evaluation of illness severity; often normal in toxic patients despite high fever (Syrjala, 1986b; Evans et al, 1985) (Francis, 1925) (Pullen & Stuart, 1945; Giddens et al, 1957; Dienst, 1963).
    2) White blood cell differential is usually normal, especially early in course (mean, 13th day); lymphocytosis seen later (mean, 29th day) (Evans et al, 1985; Syrjala, 1986b).
    3) Erythrocyte sedimentation rate is elevated in direct proportion to disease activity; not helpful in establishing diagnosis or patient management (determination of duration of antibiotic therapy) (Syrjala, 1986b; Dienst, 1963).
    4) MENINGEAL TULAREMIA: CSF findings are nonspecific and include less than 1000 WBC/mm(3), with mononuclear pleocytosis; protein level greater than 100; glucose level less than 30 mg/mL; may be bloody (Rogers, 1998) (Hutton & Everett, 1985; Harper et al, 1986) (Lovell, 1986)(Alfes & Ayers, 1990).
    B) BLOOD/SERUM CHEMISTRY
    1) Abnormality of at least one liver enzyme is noted in about 60% of patients; values do not correlate well with clinically detectable abdominal findings or clinical type of tularemia (Evans et al, 1985).
    2) Elevated creatine kinase levels (with or without rhabdomyolysis) is associated with a poor outcome (Penn & Kinasewitz, 1987).
    4.1.3) URINE
    A) URINALYSIS
    1) Sterile pyuria is noted in 20% to 30% of patients; finding may result in misdiagnosis as urinary tract infection (Evans et al, 1985; Penn & Kinasewitz, 1987).
    4.1.4) OTHER
    A) OTHER
    1) OTHER
    a) SKIN TEST
    1) INDICATIONS: Diagnosis of tularemia; reagent available from CDC in Atlanta, GA (Penn, 1995).
    2) FINDINGS: Reaction positive within first 7 days of illness in greater than 90% of patients (Penn, 1995).

Radiographic Studies

    A) CHEST X-RAY
    1) A chest x-ray is indicated in all suspected cases of tularemia pneumonia or patients with pulmonary signs/symptoms.
    a) FINDINGS
    1) Abnormal in about 50% of patients (Evans et al, 1985); bilateral involvement in 65%; findings nonspecific; include hilar adenopathy (most common findings), peribronchial streaking, oval infiltration, pleural effusion (Syrjala, 1985) (Dienst, 1963).
    2) Most frequent involvement is subpleural focal necrosis described as minute nodules 3 to 12 mm in diameter (50% of cases) (Dienst, 1963).
    3) Small patches of bronchopneumonia indistinct in outline and faint in density (30%); described as plaques of consolidation 2 to 5 mm in diameter scattered throughout lungs. Infiltrates difficult to visualize; may not be recognized until series of chest films is reviewed (Dienst, 1963; Evans et al, 1985).
    4) Consolidation typical finding in lobar pneumonia (Dienst, 1963).

Methods

    A) IMMUNOASSAY
    1) OVERVIEW
    a) Special culture media is required for isolation (blood-dextrose-cystine agar and other enriched media containing cystine) (Jacobs & Narain, 1983; Evans et al, 1985). F tularensis can be a slow growing organism on media and it may require several days for growth to develop (Center for Food Safety and Applied Nutrition (CFSAN), 2012).
    b) Serum agglutination tests and ELISA are the basis for serological diagnosis (Gill & Cunha, 1997). Biosafety level 2 is recommended for clinical laboratory work with potentially infective material, and biosafety level 3 is required for culturing the organism in large quantities due to the propensity of organisms to aerosolize from agar culture plates (Jacobs, 1997). Tularemia infection produces a classic polyclonal antibody response.
    c) Obtaining cultures of ulcers, lymph nodes, sputum, or other tissues not recommended in general clinical microbiology laboratories because of risk to laboratory personnel of aerosol inhalation of organism (Jacobs & Narain, 1983; Evans et al, 1985; Klotz et al, 1987; Gill & Cunha, 1997).
    2) SPUTUM GRAM STAIN
    a) A sputum gram stain is usually not helpful in diagnosis of tularemia pneumonia (Evans, 1985).
    3) BLOOD CULTURE
    a) INDICATIONS: Suspected tularemia pneumonia or typhoidal tularemia (Klotz et al, 1987).
    b) FINDINGS: Usually negative; may yield organism if appropriate culture medium or a radiometric blood culture system is used (Evans et al, 1985; Klotz et al, 1987; Penn & Kinasewitz, 1987; Reary & Klotz, 1988; Provenza et al, 1986).
    4) SKIN LESION CULTURE
    a) Obtaining cultures of ulcers not recommended in general clinical microbiology laboratories because of risk to laboratory personnel of aerosol inhalation of organism (Jacobs & Narain, 1983; Evans et al, 1985; Klotz et al, 1987). An eschar culture, which remained sterile on standard bacteriological media, yielded bacterium with the homogenous specimen by the centrifugation-shell vial technique.
    5) LYMPH NODE ASPIRATE CULTURE
    a) Obtaining cultures of lymph nodes not recommended in general clinical microbiology laboratories because of risk to laboratory personnel of aerosol inhalation of organism (Jacobs & Narain, 1983; Evans et al, 1985; Klotz et al, 1987).
    6) POLYMERASE CHAIN REACTION ASSAY
    a) Polymerase chain reaction assay (PCR) can detect F tularensis DNA in clinical specimens, including blood, skin lesions, and lymph node aspirate. Offers more timely diagnostic information than serologic methods, decreases risk of laboratory accidents with F tularensis cultures, and can be used in cases in which antibiotic therapy has been started (Dolan et al, 1998; Thalhammer et al, 1998; Sjostedt et al, 1997).
    b) Real-time PCR has been used for presumptive identification of clinical samples; however, culturing of the organism on enriched media is required to confirm a diagnosis. Due to F tularensis slow growth on media, other faster growing bacteria found in the environment and/or food samples may crowd out F tularensis (Center for Food Safety and Applied Nutrition (CFSAN), 2012).
    7) AGGLUTINATION TITER
    a) INDICATIONS: (Klotz et al, 1987) (Francis, 1925) (Giddens et al, 1957; Harrell & Whitaker, 1985) (Syrjala, 1986a):
    1) Suspected tularemia based on history and clinical findings; reliable, standard method for diagnosis.
    2) Accurate diagnosis early in course difficult because diagnostic titers of tularemia agglutinins in serum may require up to 10 days or more to develop; therefore, patients often must be treated empirically, with diagnosis established retrospectively.
    3) Serology alone may be inadequate to diagnose tularemia in HIV-infected and other immunocompromised patients (Gries & Fairchok, 1996).
    b) FINDINGS: (Francis, 1925)(Giddens et al, 1957; Evans et al, 1985):
    1) Diagnosis is established by demonstration of 4-fold rise in titer or with single convalescent titer of 1:160 or greater.
    2) Agglutinins usually first detectable from 10th to 14th day of illness; titer rises abruptly to >/=1:640 within next week; reaches maximum (generally >1:1280) about 4th to 8th week of illness.
    8) DIRECT FLUORESCENT ANTIBODY
    a) Direct fluorescent antibody (DFA) has been used for presumptive identification of clinical samples; however, culturing of the organism on enriched media is required to confirm a diagnosis. Due to F tularensis slow growth on media, other faster growing bacteria found in the environment and/or food samples may crowd out F tularensis (Center for Food Safety and Applied Nutrition (CFSAN), 2012).
    9) ENYZME-LINKED IMMUNOSORBENT ASSAY
    a) ELISA-based techniques has been used for presumptive identification of clinical samples; however, culturing of the organism on enriched media is required to confirm a diagnosis. Due to F tularensis slow growth on media, other faster growing bacteria found in the environment and/or food samples may crowd out F tularensis (Center for Food Safety and Applied Nutrition (CFSAN), 2012).
    b) ELISA has been used to measure cell-mediated and humoral immune responses following vaccination with live strains of Francisella tularensis (Waag et al, 1995).
    10) CHEMILUMINESCENT IMMUNOASSAY (CLIA)
    a) Vidziunaite et al (1995) described a chemiluminescent immunoassay (CLIA) method for the detection of tularemia antigens.
    B) FOOD ANALYSIS
    1) Detection of F tularensis by culture in a food sample is difficult because of the slow growth of the organism. A newer real-time PCR method has been created to isolate F tularensis (Center for Food Safety and Applied Nutrition (CFSAN), 2012).
    C) OTHER
    1) C-REACTIVE PROTEIN is elevated in direct proportion to disease activity; levels greater than 50 mg/dL may be indicative of severe disease; it does not allow differentiation from viral diseases (Syrjala, 1986b) or other causes of an elevated c-reactive protein.

Life Support

    A) Support respiratory and cardiovascular function.

Patient Disposition

    6.3.3) DISPOSITION/INHALATION EXPOSURE
    6.3.3.1) ADMISSION CRITERIA/INHALATION
    A) Patients require admission for observation and administration of antibiotic therapy (Jacobs et al, 1985).
    B) Acutely ill patients in whom the diagnosis is uncertain require hospitalization for further evaluation (Christenson, 1984).
    6.3.3.3) CONSULT CRITERIA/INHALATION
    A) Infectious disease consult should be obtained for patients in whom the diagnosis is uncertain or who have persistently high fever.
    6.3.6) DISPOSITION/BITE-STING EXPOSURE
    6.3.6.1) ADMISSION CRITERIA/BITE-STING
    A) Patients require admission for observation and administration of antibiotic therapy (Jacobs et al, 1985).
    B) Acutely ill patients in whom the diagnosis is uncertain require hospitalization for further evaluation (Christenson, 1984).
    6.3.6.3) CONSULT CRITERIA/BITE-STING
    A) Infectious disease consult should be obtained for patients in whom diagnosis is uncertain or who have persistently high fever.

Monitoring

    A) Chest x-ray is indicated in suspected tularemia pneumonia or patients with pulmonary signs/symptoms.
    B) Serum agglutination and ELISA tests are the basis for serological diagnosis. Biosafety level 2 is recommended for clinical laboratory work with potentially infective material, and biosafety level 3 is required for culturing the organism in large quantities.
    C) Elevated creatine kinase levels (with or without rhabdomyolysis) are associated with a poor outcome.

Oral Exposure

    6.5.1) PREVENTION OF ABSORPTION/PREHOSPITAL
    A) DECONTAMINATION
    1) Oral decontamination measures following exposure to Francisella tularensis have not been proven to be effective and are NOT recommended.
    2) EYE IRRIGATION, ROUTINE: Remove contact lenses and irrigate exposed eyes with copious amounts of room temperature 0.9% saline or water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist after 15 minutes of irrigation, an ophthalmologic examination should be performed (Peate, 2007; Naradzay & Barish, 2006).
    3) DECONTAMINATION: Remove contaminated clothing and wash exposed area thoroughly with soap and water for 10 to 15 minutes. A physician may need to examine the area if irritation or pain persists (Burgess et al, 1999).
    6.5.2) PREVENTION OF ABSORPTION
    A) SUMMARY
    1) General decontamination measures are not expected to be of benefit following oral exposure to F tularensis.
    6.5.3) TREATMENT
    A) SUPPORT
    1) Treatment should include recommendations listed in the INHALATION EXPOSURE section when appropriate.

Inhalation Exposure

    6.7.2) TREATMENT
    A) DETERMINATION OF PROGNOSIS
    1) Early diagnosis and treatment results in complete recovery in most cases (Harrell & Whitaker, 1985); however, case fatality rate with all forms of untreated disease is approximately 35% (Evans et al, 1985).
    2) Factors associated with poor outcome include (Penn & Kinasewitz, 1987):
    a) Serious underlying medical disease.
    b) Delay in seeking medical attention.
    c) Delay in initiation of antimicrobial therapy due to lack of definitive diagnosis or use of antibiotics other than aminoglycosides.
    d) Bacteremia.
    e) Elevated CPK levels (with or without rhabdomyolysis).
    f) Undiagnosed tularemia pneumonia.
    3) IMMUNITY: Recovery associated with development of immunity appears life-long; second episodes occur but are mild (Francis, 1925).
    B) AIRWAY MANAGEMENT
    1) In cases of airway compromise or respiratory failure secondary to pneumonic tularemia, supportive measures include endotracheal intubation and mechanical ventilation.
    C) ANTIBIOTIC
    1) SUMMARY
    a) Empiric therapy often must be instituted since laboratory confirmation of seroconversion may take days, which will delay initiation of therapy. Particularly indicated with strong suspicion of active disease and in seriously ill patients with presumptive evidence of tularemia (Penn, 1995). Parenteral therapy with an aminoglycoside is recommended initially for treatment of pulmonary and typhoidal tularemia (Dennis et al, 2001).
    b) HIV-infected and other immunocompromised patients infected with tularemia may require more extended courses of antibiotic therapy (Gries & Fairchok, 1996).
    2) ROUTE
    a) Parenteral therapy is recommended initially for treatment of pulmonary and typhoidal tularemia and for acutely ill patients with ulceroglandular or glandular tularemia. Treatment with aminoglycosides should be continued for the entire course. Patients treated initially with anything other than an aminoglycoside may be switched from IV to oral therapy once the acute illness is controlled. Oral therapy is appropriate for mild to moderate cases of ulceroglandular or glandular tularemia (Stevens et al, 2005; Dennis et al, 2001).
    b) If tularemia is used as a biological weapon, parenteral therapy is recommended initially in a contained casualty setting (ie, logistics permit individual medical management). In a mass casualty situation, oral therapy is acceptable (Dennis et al, 2001).
    3) PREGNANCY
    a) In the setting of bioterrorism, treatment of pulmonary tularemia in pregnant women is similar to that for nonpregnant adults. In a contained casualty setting, short courses of gentamicin are likely to pose a low risk to fetuses, and the benefits are expected to outweigh the risks. In a mass casualty setting, oral ciprofloxacin is considered the best alternative to gentamicin (Dennis et al, 2001).
    4) IMMUNOCOMPROMISED
    a) Streptomycin or gentamicin should be used whenever possible in HIV-infected and other immunocompromised patients infected with tularemia (Dennis et al, 2001). Immunocompromised patients may require a more extended courses of antibiotic therapy (Gries & Fairchok, 1996a).
    5) POSTEXPOSURE PROPHYLAXIS
    a) In the setting of bioterrorism, postexposure antibiotic prophylaxis may be of benefit if the antibiotics are given during the early incubation period (Dennis et al, 2001). Prophylaxis is also indicated following a possible laboratory exposure with a high risk of infection. Exposed persons with low-risk exposures can be placed on a fever watch and treated if they develop symptoms (Dennis et al, 2001).
    b) Treatment of close contacts is not recommended because person-to-person transmission of F tularensis is not known to occur (Dennis et al, 2001).
    6) DRUGS OF CHOICE
    a) Empiric antibiotic therapy must be instituted on clinical and historical grounds, without laboratory confirmation, in seriously ill patients with a strong suspicion of tularemia (Dennis et al, 2001).
    b) Aminoglycosides (eg, streptomycin, gentamicin, tobramycin) are the drugs of choice for parenteral therapy. Doxycycline is an alternative choice; however, relapses and primary treatment failures occur at a higher rate than with aminoglycosides. The only potential advantage of doxycycline is its ability to cover coexisting or other tick-borne pathogens if a specific diagnosis is uncertain. A fluoroquinolone (eg, ciprofloxacin or levofloxacin) is another alternative choice in adults (Stevens et al, 2005); however, prescribing ciprofloxacin for tularemia is an off-label use, although it has proven its efficacy against F tularensis (Dennis et al, 2001).
    c) Doxycycline and chloramphenicol are alternative choices but are less effective. Oral tetracycline may be a reasonable alternative in less severe cases; also may be used to complete therapy following initial treatment with an aminoglycoside. Chloramphenicol should be considered in patients suspected of having tularemic meningitis (Enderlin et al, 1994; Penn, 1995; Evans et al, 1985).
    d) Limited data suggest possible efficacy of quinolones (ciprofloxacin, norfloxacin) (Syrjala et al, 1991; Risi & Pombo, 1995; Enderlin et al, 1994).
    e) LACK OF EFFECT: Ceftriaxone is ineffective therapy for tularemia (Cross & Jacobs, 1993). However, in meningitic tularemia, a third-generation cephalosporin given with an aminoglycoside may prove to be more effective and safer than chloramphenicol (Penn, 1995).
    f) STREPTOMYCIN
    1) INDICATIONS: Drug of choice for moderate to severe non-meningitic tularemia, although gentamicin has comparable efficacy and is an acceptable alternative choice. Add chloramphenicol if meningitis is suspected (Sanford, 1997).
    2) RECOMMENDATIONS for suspected and known illness:
    a) TULAREMIA: ADULT: 1 g IM twice daily for 10 days (Dennis et al, 2001); OR 1 to 2 g/day IM in divided doses for 7 to 10 days until the patient is afebrile for 5 to 7 days (Prod Info Streptomycin intramuscular injection, 2011); PEDIATRIC: 15 mg/kg IM twice daily for 10 days (maximum 2 g/day) (Dennis et al, 2001).
    3) Oral doxycycline may be used to complete a course of therapy following clinical stabilization with streptomycin (Liles & Burger, 1993).
    g) GENTAMICIN
    1) INDICATIONS: A drug of choice for moderate to severe non-meningitic tularemia in adults and children (Penn, 1995; Cross et al, 1995); has comparable efficacy to streptomycin (Enderlin et al, 1994; Cross et al, 1995). Add chloramphenicol if meningitis is suspected (Penn, 1995).
    2) RECOMMENDATIONS for suspected and known illness:
    a) PULMONARY TULAREMIA: ADULT: 5 mg/kg IV or IM once daily for 10 days; PEDIATRIC: 2.5 mg/kg IV or IM 3 times daily for 10 days (Dennis et al, 2001).
    b) TYPHOIDAL TULAREMIA: ADULT: 5 mg/kg IV or IM once daily for 7 to 14 days; PEDIATRIC: 2.5 mg/kg IV or IM 3 times daily for 7 to 14 days (Gilbert et al, 2005).
    h) DOXYCYCLINE
    1) INDICATIONS
    a) May be used to complete a course of therapy following clinical stabilization with streptomycin or gentamicin (Liles & Burger, 1993).
    b) Alternative agent in less severe cases, but is less effective than aminoglycosides (Penn, 1995; Enderlin et al, 1994; Leggiadro, 1991). Do NOT use doxycycline as initial therapy in severe cases. Relapses occur in 50% to 60% of cases, especially if patient is treated early in course (within 7 days) or with an insufficient course of aminoglycosides (less than 2 weeks) (Enderlin et al, 1994; Evans et al, 1985; Liles & Burger, 1993).
    c) ROUTE: Doxycycline is appropriate for oral therapy (Stevens et al, 2005; Dennis et al, 2001).
    7) BIOLOGIC WEAPON THERAPY
    a) CONTAINED CASUALTY SETTING EXPOSED TO TULAREMIA
    1) PREFERRED THERAPIES
    a) STREPTOMYCIN: ADULT and PREGNANT WOMEN: 1 g IM twice daily for 10 days; PEDIATRIC: 15 mg/kg IM twice daily for 10 days (should not exceed 2 g/day) (Dennis et al, 2001).
    b) GENTAMICIN: ADULT and PREGNANT WOMEN: 5 mg/kg IM or IV once daily for 10 days; PEDIATRIC: 2.5 mg/kg IM or IV 3 times daily for 10 days (Dennis et al, 2001).
    2) ALTERNATIVE THERAPIES
    a) DOXYCYCLINE: ADULT and PREGNANT WOMEN: 100 mg IV twice daily for 14 to 21 days; PEDIATRIC: Children greater than 45 kg: 100 mg IV twice daily for 14 to 21 days OR Children less than 45 kg: 2.2 mg/kg IV twice daily for 14 to 21 days (Dennis et al, 2001).
    b) CHLORAMPHENICOL: Chloramphenicol is one of the alternative antibiotics recommended by the Working Group on Civilian Biodefense for the treatment of tularemia (caused by F tularensis), in a setting of intentional (biological weapon) release. Chloramphenicol has been used successfully for treating naturally occurring tularemia in adults and children; however, treatment failures and relapses occur more often with chloramphenicol than with the aminoglycosides (Dennis et al, 2001a).
    1) DOSE: ADULT and PEDIATRIC: The recommended IV dose is 15 mg/kg every 6 hours for 14 to 21 days. A switch to oral antibiotics should be made when clinically indicated (Dennis et al, 2001a).
    c) CIPROFLOXACIN: ADULT and PREGNANT WOMEN: 400 mg IV twice daily for 14 to 21 days; PEDIATRIC: 15 mg/kg IV twice daily for 14 to 21 days (maximum dose: 1 g/day in children) (Dennis et al, 2001).
    b) MASS CASUALTY SETTING or POSTEXPOSURE PROPHYLAXIS
    1) PREFERRED THERAPIES
    a) DOXYCYCLINE: ADULT and PREGNANT WOMEN: 100 mg orally twice daily for 14 days; PEDIATRIC: Children greater than 45 kg: 100 mg orally twice daily for 14 days OR Children less than 45 kg: 2.2 mg/kg orally twice daily for 14 days (Dennis et al, 2001).
    b) CIPROFLOXACIN: ADULT and PREGNANT WOMEN: 500 mg orally twice daily for 14 days; PEDIATRIC: 15 mg/kg orally twice daily for 14 days (Dennis et al, 2001).
    8) MANAGEMENT GUIDELINES FOR LABORATORY EXPOSURES
    1) ASSESSMENT OF POST-EXPOSURES
    a) MODERATE/HIGH RISK
    1) INHALATION: Defined as not wearing a respirator with direct splash of an infectious agent or aerosolized dried agent outside of BSC; or exposure from centrifuge accident with viable organism; or break in respiratory protection in an environment with an infectious agent or animal with potential to be aerosolized.
    2) PERCUTANEOUS/CUTANEOUS: Percutaneous exposure to any of the following: needle or blade with prior contact with a solution containing the agent; or contact with blood/fluids of an infected animal that is ill or likely to have the organism in the blood/fluids. Cuts from any source that might contain the infectious agent or contact with intact skin, but a delay in cleaning the area.
    b) MINIMAL-RISK EXPOSURE
    1) INHALATION: Defined as an exposure to an organism that is unlikely to be aerosolized or spill that is contained within the BSC or an exposure to an infectious agent that is unlikely to be aerosolized.
    2) PERCUTANEOUS/CUTANEOUS: Percutaneous exposure to any of the following: from needle or blade with prior blood/fluids of an animal infected with an agent, but the animal not likely to be bacteremic or shedding organisms; or scratch or bite from an animal infected with an agent, but not likely to be ill. Direct contact with infectious agent to skin, but cleaned immediately.
    c) NEGLIGIBLE OR NO RISK-EXPOSURE
    1) INHALATION or PERCUTANEOUS: No discernible contact with either an aerosolized or percutaneous/cutaneous (eg, needle stick, abrasion or cuts to skin) infectious agent or an infected animal. Injury or break in laboratory technique, but not in the presence of an infected animal or organism.
    a) BACKGROUND: Laboratory researchers working with potential Francisella tularensis are usually given a live vaccine (not currently FDA approved) with booster doses as needed per microagglutination titer (Rusnak et al, 2004).
    b) POSTEXPOSURE ANTIBIOTIC PROPHYLAXIS REGIMENS: Based on work conducted by the Special Immunizations Program at the United States Army Medical Research Institute of Infectious Diseases, the following recommendations are suggested for postexposure prophylaxis in laboratory workers exposed to bioterrorism agents. The guidelines are based on the risk of exposure, the virulence of the organism, and vaccination status of the individual (Rusnak et al, 2004a).
    c) Currently, the guidelines recommend prophylactic antibiotic therapy for all moderate or high-risk exposures regardless of vaccination status. Prophylaxis was also recommended for unvaccinated individuals with minimal risk exposures. Lastly, clinical judgement should guide prophylactic therapy on a case-by-case basis (Rusnak et al, 2004a).
    d) PROPHYLACTIC REGIMEN: F. tularensis: Doxycycline or ciprofloxacin for 14 days is recommended (Rusnak et al, 2004a).
    D) ANTIPYRETIC
    1) ANTIPYRETICS/ANALGESICS: Indicated for control of fever, headache, and muscle pains.
    a) ASPIRIN (Adults only) or ACETAMINOPHEN: 650 mg (children: 15 mg/kg) orally every 4 to 6 hours or IBUPROFEN 600 to 800 mg (children: 5 to 10 mg/kg) orally every 8 hours.
    E) VACCINE
    1) Tularemia vaccine is indicated for persons requiring protection against tularemia, but is not commercially available. It is available from the US Army Medical Research Institute (USAMRIID), Fort Detrick, MD, 21701. Vaccine is produced from live, attenuated strains of F. tularensis (Jacobs, 1997; Sandstrom, 1994).
    2) A single dose of live vaccine is administered intradermally by multiple-pressure technique. After 3 weeks, protection to aerosol challenge is demonstrated and immunity to 1 to 10 ID50 is present in 80% of vaccinated subjects. Booster vaccine may be needed after one year (Wiener, 1996).
    F) REFERRAL TO PUBLIC HEALTH SERVICE
    1) REPORTING: All confirmed and suspected cases should be reported immediately through local and state health departments to the Centers for Disease Control (CDC). Health department personnel will work with the CDC and the attending physician in the treatment of tularemia.
    G) Treatment should include recommendations listed in the ORAL EXPOSURE section when appropriate.

Eye Exposure

    6.8.1) DECONTAMINATION
    A) Exposed eyes should be irrigated with copious amounts of room temperature water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist after 15 minutes of irrigation, an ophthalmologic examination should be performed.
    6.8.2) TREATMENT
    A) SUPPORT
    1) Treatment should include recommendations listed in the INHALATION EXPOSURE section when appropriate.
    B) Treatment should include recommendations listed in the ORAL EXPOSURE section when appropriate.

Dermal Exposure

    6.9.1) DECONTAMINATION
    A) INTACT SKIN should be thoroughly washed with soap under running water.
    B) CUTS should be irrigated thoroughly.
    C) Wash exposed area extremely thoroughly with soap and water. A physician may need to examine the area if irritation or pain persists after washing.
    6.9.2) TREATMENT
    A) SUPPORT
    1) Treatment should include recommendations listed in the INHALATION EXPOSURE section when appropriate.
    B) Treatment should include recommendations listed in the ORAL EXPOSURE section when appropriate.

Summary

    A) TOXICITY: Mortality is less than 2% if treated; can be 30% in cases of typhoidal tularemia with pneumonia. Risk of infection related to degree of exposure and virulence of the organism. INHALATION: As few as 10 organisms can result in illness. INGESTION: Larger doses of bacteria (approximately 1 to 10 million) are needed to produce gastrointestinal infection. The organism can survive long periods.

Minimum Lethal Exposure

    A) SUMMARY
    1) Inhalation of Francisella tularensis organisms may result in a septicemic typhoidal disease or a primary pneumonia. In a biologic terrorist attack, pneumonic tularemia is a primary concern. Clinical course may be rapidly progressive and fulminant. Without antibiotic treatment, mortality rates range from 30% to 60%. With therapy, mortality drops to 1% to 2.5% (McGovern et al, 1999).
    B) INFECTIVE DOSE
    1) INHALATION: As few as 10 organisms can result in illness (Center for Food Safety and Applied Nutrition (CFSAN), 2012).
    2) INGESTION: Larger doses of bacteria (approximately 1 to 10 million) are needed to produce gastrointestinal infection (Center for Food Safety and Applied Nutrition (CFSAN), 2012).
    C) ANIMAL DATA
    1) Gurycova (1998) reported that 1 to 1000 cells of Francisella tularensis subsp. tularensis (SE-219, SE-221) infected subcutaneously in rabbits were lethal (Gurycova, 1998).

Maximum Tolerated Exposure

    A) SUMMARY
    1) It has been reported that cutaneous or pulmonary tularemia infection may be caused by as few as 10 Francisella tularensis organisms (McGovern et al, 1999; Fisher, 1996).
    2) F. tularenis type B (found in Europe) produces milder clinical symptoms than type A and rarely causes death in humans (Feldman et al, 2001).
    3) Cutaneous multiplication of organisms can allow the organism to spread to lymph nodes and then to blood (McGovern et al, 1999).

Toxicologic Mechanism

    A) VIRULENCE: Humans are highly susceptible to F tularensis infection; 10 organisms injected SC and 10 to 50 given by aerosol can cause infection (Center for Food Safety and Applied Nutrition (CFSAN), 2012). F tularensis is an intracellular pathogen; specific host resistance depends mainly on cell-mediated immunity (Claffin & Larson, 1972).
    1) Routes of infection include respiratory, intradermal, and occasionally gastrointestinal; further dissemination is by blood or lymphatics. Bacteremia is usually present during the first week after infection; spread to regional and distant lymph nodes, liver, spleen, and lungs may occur (Dienst, 1963).

General Bibliography

    1) Alfes JC & Ayers LW: Acute bacterial meningitis caused by Francisella tularensis. Pediatr Infect Dis J 1990; 9:300-301.
    2) Anon: CDC: Brief report: tularemia associated with a hamster bite-colorado, 2004. MMWR 2005; 53:1202-1203.
    3) Billings AN, Rawlings JA, & Walker DH: Tick-borne diseases in Texas: a 10-year retrospective examination of cases. Texas Med 1998; 94:66-76.
    4) Burgess JL, Kirk M, Borron SW, et al: Emergency department hazardous materials protocol for contaminated patients. Ann Emerg Med 1999; 34(2):205-212.
    5) CDC: Tularemia - New Jersey. CDC: MMWR 1986; 35:747-748&-753.
    6) Capellan J & Fong IW: Tularemia from a cat bite: case report and review of feline-associated tularemia. Clin Infect Dis 1993; 16:472-475.
    7) Caruso VG, Caruso AP, & Panebianco RJ: Oropharyngeal tularemia. State J Med 1983; 83:226-227.
    8) Center for Food Safety and Applied Nutrition (CFSAN): Francisella tularensis. In: Bad Bug Book Foodborne Pathogenic Microorganisms and Natural Toxins Handbook Second Edition. U.S. Food and Drug Administration (FDA). College Park, MD. 2012. Available from URL: http://www.fda.gov/downloads/Food/FoodSafety/FoodborneIllness/FoodborneIllnessFoodbornePathogensNaturalToxins/BadBugBook/UCM297627.pdf. As accessed 2013-03-13.
    9) Centers for Disease Control and Prevention: Tularemia--Oklahoma, 2000. MMWR Morb Mortal Wkly Rep 2001; 50(33):704-706.
    10) Chappell CW, Brainard J, & Shock JP: Oculoglandular tularemia - a case report. J Ark Med Soc 1981; 78:128-130.
    11) Christenson B: An outbreak of tularemia in the northern part of central Sweden. Scand J Infect Dis 1984; 16:285-290.
    12) Claffin JL & Larson CL: Infection-immunity in tularemia: Specificity of cellular immunity. Infect Immun 1972; 5:311-318.
    13) Cross JT & Jacobs RF: Tularemia: treatment failures with outpatient use of ceftriaxone. Clin Infect Dis 1993; 17:976-980.
    14) Cross JT Jr, Schutze GE, & Jacobs RF: Treatment of tularemia with gentamicin in pediatric patients. Pediatr Infect Dis J 1995; 14:151-152.
    15) Dennis DT, Inglesby TV, Henderson DA, et al: Tularemia as a biological weapon: medical and public health management. JAMA 2001a; 285(21):2763-2773.
    16) Dennis DT, Inglesby TV, Henderson DA, et al: Tularemia as a biological weapon: medical and public health management.. JAMA 2001; 285:2763-2773.
    17) Dienst FT Jr: Tularemia: a perusal of three hundred thirty-nine cases. J La State Med Soc 1963; 115:114-127.
    18) Dolan SA, Dommaraju CB, & DeGuzman GB: Detection of Francisella tularensis in clinical specimens by use of polymerase chain reaction. Clin Infect Dis 1998; 26:764-765.
    19) Enderlin G, Morales L, Jacobs RF, et al: Streptomycin and alternative agents for the treatment of tularemia: review of the literature.. Clin Infect Dis 1994; 19:42-47.
    20) Evans ME, Gregory DW, & Schaffner W: Tularemia: a 30-year experience with 88 cases. Medicine 1985; 64:251-269.
    21) Everett ED & Templer JW: Oropharyngeal tularemia. Arch Otolaryngol 1980; 106:237-238.
    22) Feldman KA, Enscore RE, Lathrop SL, et al: An outbreak of primary pneumonic tularemia on Martha's Vineyard.. N Engl J Med 2001; 345:1601-1606.
    23) Fisher RG: Index of suspicion. Pediatr Rev 1996; 17:221-223.
    24) Fredricks DN & Remington JS: Tularemia presenting as community-acquired pneumonia. Arch Intern Med 1996; 156:2137-2140.
    25) Funk LM, Simpson SQ, & Mertz G: Tularemia presenting as an isolated pleural effusion. West J Med 1992; 156:415-417.
    26) Garrett CL: Tularemia fatality (letter). NC Med J 1995; 56:476.
    27) Garver MK, St Geme JW, & Siegel MJ: Tularemia presenting with splenic nodules. Pediatr Infect Dis J 1994; 13:830-832.
    28) Giddens WR, Wilson JW Jr, & Dienst FT Jr: Tularemia: an analysis of one hundred forty-seven cases. J La State Med Soc 1957; 109:93-98.
    29) Gilbert DN, Moellering RC Jr, Eliopoulos GM, et al (Eds): The Sanford Guide to Antimicrobial Therapy 2005, 35th ed. Antimicrobial Therapy, Inc, Hyde Park, VT, USA, 2005.
    30) Gill V & Cunha BA: Tularemia pneumonia. Sem Resp Infect 1997; 12:61-67.
    31) Gries DM & Fairchok MP: Typhoidal tularemia in a human immunodeficiency virus-infected adolescent. Pediatr Infect Dis J 1996; 15:838-840.
    32) Gries DM & Fairchok MP: Typhoidal tularemia in a human immunodeficiency virus-infected adolescent.. Pediatr Infect Dis J 1996a; 15:838-840.
    33) Guerrant RL, Humphries MK, & Butler JE: Tickborne oculoglandular tularemia: case report and review of seasonal and vectorial associations in 106 cases. Arch Intern Med 1976a; 136:811-813.
    34) Guerrant RL, Humphries MK, Butler JE, et al: Tickborne oculoglandular tularemia: case report and review of seasonal and vectorial associations in 106 cases.. Arch Intern Med 1976; 136:811-813.
    35) Gurycova D: First isolation of Francisella tularensis subsp. Tularensis in Europe. Eur J Epidemiol 1998; 14:797-802.
    36) Halperin SA, Gast T, & Ferrieri P: Oculoglandular syndrome caused by Francisella tularensis. Clin Pediatr 1985; 24:520-522.
    37) Harper JL, Florman AL, & Tso W: Tularemic meningitis in a child with mononuclear pleocytosis. Pediatr Infect Dis 1986; 5:595-597.
    38) Harrell RE Jr & Whitaker GR: Tularemia: emergency department presentation of an infrequently recognized disease. Am J Emerg Med 1985; 3:415-418.
    39) Honig PJ: Arthropod bites, stings, and infestations: their prevention and treatment. Pediatr Dermatol 1986; 3:189-197.
    40) Hopla CE: The ecology of tularamia. Adv Vet Sci Comp Med 1974; 18:25-53.
    41) Hughes WT Jr: Oculoglandular tularemia: transmission from rabbit, through dog and tick to man. Pediatrics 1965; 36:270-272.
    42) Hutton JP & Everett ED: Response of tularemic meningitis to antimicrobial therapy. South Med J 1985; 78:189-190.
    43) Jacobs RF & Narain JP: Tularemia in children. Pediatr Infect Dis 1983; 2:487-491.
    44) Jacobs RF, Condrey YM, & Yamauchi T: Tularemia in adults and children: a changing presentation. Pediatrics 1985; 76:818-822.
    45) Jacobs RF: Tularemia. Adv Pediatr Infect Dis 1997; 12:55-69.
    46) Kammholz LP: Variation on tick removal (letter). Pediatrics 1986; 78:378-379.
    47) Klotz SA, Penn RL, & Provenza JM: The unusual presentation of tularemia: bacteremia, pneumonia, and rhabdomyolysis. Arch Intern Med 1987; 147:214.
    48) Kodama BF, Fitzpatrick JE, & Gentry RH: Tularemia. Cutis 1994; 54:279-280.
    49) Langley R & Campbell R: Tularemia in North Carolina, 1965-1990. N C Med J 1995; 56:314-317.
    50) LeDoux MS: Tularemia presenting with ataxia.. Clin Infect Dis 2000; 30:211-212.
    51) Lee MD, Sonenshine DE, & Counselman FL: Evaluation of subcutaneous injection of local anesthetic agents as a method of tick removal. Am J Emerg Med 1995; 13:14-16.
    52) Leggiadro RJ, Kenigsberg K, & Annunziato D: Tick-borne ulceroglandular tularemia. State J Med 1983; 83:1053-1054.
    53) Leggiadro RJ: Tetracycline for Rocky Mountain spotted fever. Pediatrics 1991; 87:124-125.
    54) Liles WC & Burger RJ: Tularemia from domestic cats. West J Med 1993; 158:619-622.
    55) Lovell VM, Cho CT, Lindsey NJ, et al: Francisella tularensis meningitis: a rare clinical entity.. J Infect Dis 1986; 154:916-918.
    56) Luotonen J, Syrjala H, & Jokinen K: Tularemia in otolaryngologic practice: an analysis of 127 cases. Arch Otolaryngol Head Neck Surg 1986; 112:77-80.
    57) McChesney TC & Narain J: A five-year evaluation of tularemia in Arkansas. J Ark Med Soc 1983; 80:257-262.
    58) McGovern TW, Christopher GW, & Eitzen EM: Cutaneous manifestations of biological warfare and related threat agents. Arch Dermatol 1999; 135:311-322.
    59) Myers JP & Baird IM: Tularemia in Ohio: report of two cases and clinical review. Am J Med Sci 1981; 282:148-152.
    60) Naradzay J & Barish RA: Approach to ophthalmologic emergencies. Med Clin North Am 2006; 90(2):305-328.
    61) Naughton M, Brown R, & Adkins D: Tularemia - an unusual cause of a solitary pulmonary nodule in the post-transplant setting. Bone Marrow Transplant 1999; 24:197-199.
    62) Needham GR: Evaluation of five popular methods for tick removal. Pediatrics 1985; 75:997-1002.
    63) None Listed: Case records of the Massachusetts general hospital. weekly clinicopathological exercises. Case 14-2000. a 60-year-old farm worker with bilateral pneumonia. N Engl J Med 2000; 342(19):1430-1438.
    64) Nordahl SHD, Hoel T, & Scheel O: Tularemia: a differential diagnosis in oto-rhino-laryngology. J Laryngol Otol 1993a; 107:127-129.
    65) Nordahl SHD, Hoel T, Scheel O, et al: Tularemia: a differential diagnosis in oto-rhino-laryngology.. J Laryngol Otol 1993; 107:127-129.
    66) Ohara Y, Sato T, & Homma M: Arthropod-borne tularemia in Japan: clinical analysis of 1,374 cases observed between 1924 and 1996. J Med Entomol 1998; 35:471-473.
    67) Ohara Y, Sato T, Fujita H, et al: Clinical manifestations of tularemia in Japan - analysis of 1,355 cases observed between 1924 and 1987.. Infection 1991; 19:18-21.
    68) Parkhurst JB & San Joaquin VH: Tonsillopharyngeal tularemia: a reminder (letter). Am J Dis Child 1990; 144:1070-1071.
    69) Parssinen O & Rummukainen M: Acute glaucoma and acute corneal oedema in association with tularemia. Acta Ophthalmol Scand 1997; 75:732-734.
    70) Peate WF: Work-related eye injuries and illnesses. Am Fam Physician 2007; 75(7):1017-1022.
    71) Penn R: Francisella tularensis (tularemia). In: Mandell GL, Bennett JE & Dolin R (Eds): Principles and Practice of Infectious Diseases, 4th ed, Churchill Livingstone, New York, NY, 1995.
    72) Penn RL & Kinasewitz GT: Factors associated with a poor outcome in tularemia. Arch Intern Med 1987; 147:265-268.
    73) Poquet Y, Kroca M, & Halary F: Expansion of vy9vd2 t cells is triggered by Francisella tularensis-derived phosphoantigens in tularemia but not after tularemia vaccination. Infect Immunity 1998; 66:2107-2114.
    74) Product Information: Streptomycin intramuscular injection, streptomycin sulfate intramuscular injection. X-Gen Pharmaceuticals (per FDA), Big Flats, NY, 2011.
    75) Provenza JM, Klotz SA, & Penn RL: Isolation of Francisella tularensis from blood. J Clin Microbiol 1986; 24:453-455.
    76) Pullen RL & Stuart BM: Tularemia: analysis of 225 cases. JAMA 1945; 129:495-500.
    77) Reary BW & Klotz SA: Enhancing recovery of Francisella tularensis from blood. Diagn Microbiol Infect Dis 1988; 11:117-119.
    78) Risi GF & Pombo DJ: Relapse of tularemia after aminoglycoside therapy: case report and discussion of therapeutic options. Clin Infect Dis 1995; 20:174-175.
    79) Rusnak JM, Kortepeter MG, Aldis J, et al: Experience in the medical management of potential laboratory exposures to agents of bioterrorism on the basis of risk assessment at the United States army medical research institute of infectious diseases (USAMRIID) . JOEM 2004; 46(8):801-811.
    80) Rusnak JM, Kortepeter MG, Hawley RJ, et al: Management guidelines for laboratory exposures to agents of bioterrorism. JOEM 2004a; 46(8):791-800.
    81) Sandstrom G: The tularaemia vaccine. J Chem Tech Biotechnol 1994; 59:315-320.
    82) Senol M, Ozcan A, & Karincaoglu Y: Tularemia: a case transmitted from a sheep. Cutis 1999; 63:49-51.
    83) Sjostedt A, Eriksson U, & Berglund L: Detection of Francisella tularensis in ulcers of patients with tularemia by PCR. J Clin Microbiol 1997; 35:1045-1048.
    84) Steinemann TL, Sheikholeslami MR, & Brown HH: Oculoglandular tularemia. Arch Ophthamol 1999; 117:132-133.
    85) Stevens DL, Bisno AL, Chambers HF, et al: Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41(10):1373-1406.
    86) Sunderrajan EV, Hutoon J, & Marienfeld RD: Adult respiratory distress syndrome secondary to tularemia pneumonia. Arch Intern Med 1985; 145:1435-1437.
    87) Syrjala H, Schildt R, & Raisainen S: In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis 1991; 10:68-70.
    88) Syrjala H: Peripheral blood leukocyte counts, erythrocyte sedimentation rate and C-reactive protein in tularemia caused by the type B strain of Francisella tularensis. Infection 1986b; 51-54.
    89) Tarnvik A, Sandstrom G, & Sjostedt A: Infrequent manifestations of tularaemia in Sweden. Scand J Infect Dis 1997; 29:443-446.
    90) Thalhammer F, Ebert G, & Kopetzki-Kogler U: Detection of Francisella tularensis in clinical specimens by use of polymerase chain reaction. Clin Infect Dis 1998; 26:764-765.
    91) Uhari M, Syrjala H, & Salminen A: Tularemia in children caused by Francisella tularensis biovar palaearctica. Pediatr Infect Dis J 1990; 9:80-83.
    92) Waag DM, McKee KT, & Sandstrom G: Cell-mediated and humoral immune responses after vaccination of human volunteers with the live vaccine strain of Francisella tularensis. Clin Diag Lab Immunol 1995; 2:143-148.
    93) Wiener SL: Strategies for the prevention of a successful biological warfare aerosol attack. Mil Med 1996; 161:251-256.
    94) Wills PI, Gedosh EA, Nichols DR, et al: Head and neck manifestations of tularemia. Laryngoscope 1982; 92:770-773.
    95) von Schroeder HP & McDougall P: Ulceroglandular and pulmonary tularemia: a case resulting from a cat bite to the hand. J Hand Surg 1993; 18a:132-134.